Key result
T1 and T2 mapping fails to discriminate EMB-proven chronic myocardial inflammation in HFrEF.
Why the study?
To evaluate the non-invasive detection of EMB-established chronic myocardial inflammation in patients with HFrEF using T1 and T2 mapping.
Does T1 and T2 mapping in cardiac magnetic resonance imaging accurately detect chronic myocardial inflammation in patients with HFrEF?
Observational (n=110)
No
Does T1 and T2 mapping in cardiac magnetic resonance imaging accurately detect chronic myocardial inflammation in patients with HFrEF?
Quantitative T1 and T2 mapping values are elevated in HFrEF patients compared to healthy controls but cannot reliably discriminate between HFrEF patients with and without EMB-proven chronic myocardial inflammation.
T1/T2 mapping should not guide chronic inflammation detection in HFrEF; leaves open validation of CMR thresholds against EMB.
AIMS: The purpose of this retrospective single-centre study was to evaluate the non-invasive detection of endomyocardial biopsy (EMB)-established chronic myocardial inflammation in patients with heart failure with reduced ejection fraction (HFrEF) using T1 and T2 mapping. METHODS AND RESULTS: The study population consisted of 52 retrospectively identified HFrEF patients who underwent EMB and cardiac magnetic resonance imaging at 3 Tesla. EMB was defined according to the position statement of the European Society of Cardiology and served as reference to identify inflammation in all patients. A control group of healthy volunteers with prior cardiac magnetic resonance imaging studies (n = 58) was also identified. Global and segmental T1 and T2 values as well as septal measurements and tissue heterogeneity parameters were calculated. Out of the 52 patients with HFrEF, 33 patients had myocardial inflammation detected by EMB, while 19 patients were EMB negative for inflammation. Mean left ventricular ejection fraction was 31% in both groups (P = 0.97). Global T1 and T2 values in HFrEF patients were significantly higher compared with healthy controls (T1 1275 ± 69 ms vs. 1,175 ± 44 ms, P < 0.001; T2 40.0 ± 3.4 ms vs. 37.9 ± 1.6 ms, P < 0.001). The distribution of T1 and T2 values between patients with and without EMB-proven chronic myocardial inflammation was not statistically different when regarding global (T1 1292 ± 71 ms vs. 1266 ± 67 ms, P = 0.26; T2 40.0 ± 2.6 ms vs. 40.0 ± 3.9 ms, P = 1.0), septal (T1 1299 ± 63 ms vs. 1289 ± 76 ms, P = 0.76; T2 40.1 ± 3.5 ms vs 40.0 ± 6.4 ms, P = 0.49) or maximum segmental values (T1 1414 ± 111 ms vs. 1363 ± 88 ms, P = 0.15; T2 47.3 ± 5.2 ms vs. 48.8 ± 11.8 ms, P = 0.53). Mean absolute deviation of segmental T1 and T2 values and log-transformed pixel-wise standard deviation as parameters of tissue heterogeneity did not reveal statistical significant differences between inflammation-positive and inflammation-negative HFrEF patients (all P > 0.4). CONCLUSIONS: Conventionally performed quantitative T1 and T2 mapping values significantly correlated with prevalence of HFrEF but did not discriminate HFrEF patients with or without chronic myocardial inflammation in our cohort. This suggests that EMB is the preferred method to detect chronic myocardial inflammation in HFrEF.
No takes yet. Share an insight, caveat, or question.
Emrich et al. (2020) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=110). T1 and T2 mapping vs. Patients without EMB-proven inflammation and healthy controls was evaluated on Global T1 and T2 values to detect chronic myocardial inflammation (p=0.26). T1 and T2 mapping did not significantly discriminate HFrEF patients with or without EMB-proven chronic myocardial inflammation (global T1 1292 vs 1266 ms, P=0.26; global T2 40.0 vs 40.0 ms, P=1.0).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: